Just Block This Right Here, Thanks

Dec 05, 2009

A hepatitis C drug from Santaris targeting a microRNA is now in the early stages of clinical testing, reports Technology Review. The drug, a synthetic nucleic acid, binds miR-122, which the hepatitis C virus needs to reproduce.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Test Evaluations

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

Justification for Stricter Standards Sought

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

Concerns Over Comment

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

PLOS Papers on Tremor Condition, Medical Plant Populations, Brewing Yeast Transcriptomics

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.

Menu